Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Average Rating of "Buy" by Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) has received a consensus rating of "Buy" from the five research firms that are currently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $36.60.

KNSA has been the subject of several recent analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. Wedbush restated an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Monday. Finally, Evercore ISI upped their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th.

Kiniksa Pharmaceuticals Stock Down 2.3 %

Kiniksa Pharmaceuticals stock traded down $0.43 during trading hours on Thursday, reaching $18.39. 424,395 shares of the company's stock were exchanged, compared to its average volume of 506,150. The firm's 50 day simple moving average is $20.85 and its 200 day simple moving average is $23.24. Kiniksa Pharmaceuticals has a twelve month low of $16.56 and a twelve month high of $28.15. The firm has a market capitalization of $1.33 billion, a PE ratio of -131.35 and a beta of 0.29.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The business had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company's revenue for the quarter was up 67.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.20) EPS. Analysts anticipate that Kiniksa Pharmaceuticals will post -0.55 EPS for the current year.

Insider Activity at Kiniksa Pharmaceuticals

In other news, CFO Mark Ragosa sold 8,969 shares of the business's stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total transaction of $192,385.05. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares of the company's stock, valued at $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Eben Tessari sold 14,000 shares of the firm's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $18.24, for a total transaction of $255,360.00. Following the completion of the transaction, the chief operating officer now directly owns 88,975 shares in the company, valued at approximately $1,622,904. The trade was a 13.60 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 24,092 shares of company stock valued at $471,609. 54.57% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP bought a new position in Kiniksa Pharmaceuticals during the 3rd quarter valued at $1,192,000. Dimensional Fund Advisors LP raised its holdings in shares of Kiniksa Pharmaceuticals by 31.2% in the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company's stock valued at $12,398,000 after purchasing an additional 157,741 shares during the last quarter. Segall Bryant & Hamill LLC bought a new position in shares of Kiniksa Pharmaceuticals during the third quarter valued at about $675,000. Parkman Healthcare Partners LLC boosted its holdings in Kiniksa Pharmaceuticals by 16.7% during the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company's stock worth $18,874,000 after purchasing an additional 108,102 shares during the last quarter. Finally, Millennium Management LLC grew its position in Kiniksa Pharmaceuticals by 159.8% in the 2nd quarter. Millennium Management LLC now owns 621,948 shares of the company's stock worth $11,612,000 after purchasing an additional 382,539 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.